Monitor pre-NDA meeting in Q3 2026 and NDA submission in Q4 2026. The stock will trade on regulatory milestones and SOL-R interim safety data in late 2026. The streamlined DR program reduces cash burn risk.
Price Chart
Executive Summary
Ocular Therapeutix announced FDA alignment to submit an NDA for AXPAXLI in wet AMD in Q4 2026 based on SOL-1 efficacy/safety data and interim SOL-R safety data, with potential for accelerated 505(b)(2) review. The company also streamlined its diabetic retinopathy program to a single registrational trial (HELIOS-3) evaluating Q12M dosing. Q1 2026 EPS of -$0.40 slightly missed consensus of -$0.39, but the regulatory catalyst dominates the narrative.
Key Financial Metrics
Key Facts
- FDA alignment to submit AXPAXLI NDA for wet AMD in Q4 2026 under 505(b)(2) pathway, potentially accelerating review by up to 60 days.
- NDA based on SOL-1 Week 52 data (primary endpoint met with p=0.0006) plus interim SOL-R safety analysis targeting >300 patients.
- SOL-R efficacy data no longer part of NDA; trial extended to Week 96 with new superiority endpoint vs aflibercept 8mg (topline 1Q 2028).
- Diabetic retinopathy program streamlined to HELIOS-3, a single registrational trial evaluating AXPAXLI Q12M vs sham (primary endpoint at Week 56).
- Q1 2026 EPS of -$0.40 missed consensus of -$0.39 by 2.6% (small miss, not material relative to regulatory update).
Financial Impact
Potential approval of AXPAXLI in wet AMD could address a multi-billion-dollar market; no financial terms disclosed in filing.
Risk Factors
- FDA may not accept NDA or may require additional data despite alignment.
- SOL-R interim safety analysis may reveal unexpected safety signals.
- Competition from existing anti-VEGF therapies (aflibercept, faricimab) could limit commercial uptake if approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313442 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access